MapLight is a biotech company focused on developing treatments for Autism Spectrum Disorder (ASD).

MapLight

Maplight is a biopharmaceutical company discovering and developing novel therapeutics for patients with disorders of the central nervous system (CNS).

Michael J. Fox Foundation

Cowen Healthcare Investments

5AM Ventures

Novo Holdings

MapLight Therapeutics, Inc.

This April, we also recognize Parkinson's Awareness Month. More than one million people in the United States are diagnosed with this debilitating condition. MapLight is tirelessly working to find another treatment option to serve them. 

Learn more about our Parkinson's research. https://lnkd.in/gjdSh2Q6

MapLight is thrilled to announce that Maria Walker has been appointed to our Board of Directors. Most recently, Maria served as the Founding Partner and Chief Financial Officer at Patient Square Capital, an investment firm dedicated to healthcare. She brings over 30 years of industry experience to the MapLight Board. Learn more via our press release. https://lnkd.in/eJ6QetSi

A reminder that tomorrow (April 4th), we are sponsoring the 11th Annual Autism Science Foundation's Day of Learning. This Autism community event includes families and individuals affected by Autism, advocates, young scientific investigators, and more to participate in TED-style presentations. We look forward to seeing our industry friends and partners in NYC! 

https://lnkd.in/eGPjmxrq

April is here – which means that it is Autism Awareness Month. Did you know that 1 in every 36 U.S. 8-year-olds has Autism Spectrum Disorder? It also affects 1 in every 45 U.S. adults. Throughout the month we'll be sharing facts, resources and events that we're attending that support the Autism community. 

In the meantime, learn more about our work with Autism Spectrum Disorder. https://lnkd.in/gxwYtiwy

Happy National Doctors' Day to all the physicians who dedicate their lives to improving the health and well-being of their patients. At MapLight Therapeutics, we extend our deepest gratitude to the Key Opinion Leaders (KOLs) who collaborate with us across all our research areas. Your insights and expertise are invaluable in our quest to advance the frontiers of medicine. Thank you for your partnership and for the extraordinary care you provide every day. https://lnkd.in/gWZG5wsj

Metric
Company Name	MapLight
Symbol
MSH ID	COM:MAPLIGHTRX
Market	PRIVATE
Sector	9
Industry	Healthcare & Health Services
Country	US
Stage	Series C
Employee Count	71
Website	maplightrx.com
LinkedIn	maplight-therapeutics-inc
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	491
Web Traffic Growth	-0.84
Valuation
Raised Capital	225M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:MAPLIGHTRX

MapLight

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue